| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Milena Damjanac, Guylène Page, Stéphanie Ragot, Guillaume Laborie, Roger Gil, Jacques Hugon, Marc Paccali. PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. Journal of cellular and molecular medicine. vol 13. issue 8B. 2010-07-19. PMID:19210572. |
in alzheimer's disease (ad), the control of translation is dysregulated, precisely, two opposite pathways: double-stranded rna-dependent protein kinase (pkr) is up-regulated and mammalian target of rapamycin (mtor) is down-regulated. |
2010-07-19 |
2023-08-12 |
Not clear |
| Margit Rosner, Christiane Fuchs, Nicol Siegel, Alessandro Valli, Markus Hengstschläge. New insights into the role of the tuberous sclerosis genes in leukemia. Leukemia research. vol 33. issue 7. 2009-05-28. PMID:19286253. |
mutations in several mtor pathway component genes are known to cause specific monogenic human genetic diseases and this signalling cascade has been shown to be of relevance for alzheimer's disease, type 2 diabetes, obesity and hypertrophy. |
2009-05-28 |
2023-08-12 |
human |
| Margit Rosner, Markus Hengstschläge. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Human molecular genetics. vol 17. issue 19. 2008-11-07. PMID:18614546. |
the distinct cytoplasmic and nuclear upstream and downstream effectors of mtor are involved in many cancers and human genetic diseases, such as tuberous sclerosis, peutz-jeghers syndrome, von hippel-lindau disease, neurofibromatosis type 1, polycystic kidney disease, alzheimer's disease, cardiac hypertrophy, obesity and diabetes. |
2008-11-07 |
2023-08-12 |
human |
| Margit Rosner, Michaela Hanneder, Nicol Siegel, Alessandro Valli, Christiane Fuchs, Markus Hengstschläge. The mTOR pathway and its role in human genetic diseases. Mutation research. vol 659. issue 3. 2008-10-14. PMID:18598780. |
in addition to all these human diseases, the role of mtor in alzheimer's disease, cardiac hypertrophy, obesity and type 2 diabetes is discussed. |
2008-10-14 |
2023-08-12 |
human |
| Milena Damjanac, Agnès Rioux Bilan, Marc Paccalin, Raymond Pontcharraud, Bernard Fauconneau, Jacques Hugon, Guylène Pag. Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease. Neurobiology of disease. vol 29. issue 2. 2008-04-04. PMID:18023354. |
previous studies demonstrated that the pkr (double-stranded rna-activated protein kinase) pathway was activated while the mtor (mammalian target of rapamycin) pathway was inhibited in alzheimer's disease (ad). |
2008-04-04 |
2023-08-12 |
mouse |
| Lukasz Swiech, Malgorzata Perycz, Anna Malik, Jacek Jaworsk. Role of mTOR in physiology and pathology of the nervous system. Biochimica et biophysica acta. vol 1784. issue 1. 2008-03-27. PMID:17913600. |
recent studies reveal that mtor activity is modified in various pathologic states of the nervous system, including brain tumors, tuberous sclerosis, cortical displasia and neurodegenerative disorders such as alzheimer's, parkinson's and huntington's diseases. |
2008-03-27 |
2023-08-12 |
Not clear |
| Daniel Zemke, Seema Azhar, Arshad Maji. The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug news & perspectives. vol 20. issue 8. 2008-03-27. PMID:18080036. |
in particular, diseases involving oxygen and nutrient deprivation, such as stroke, or diseases characterized by aggregate formation, such as alzheimer's and huntington's disease, could gain substantial benefit by either inhibiting or enhancing mtor activity. |
2008-03-27 |
2023-08-12 |
Not clear |
| Tokuhiro Chano, Hidetoshi Okabe, Christine M Hulett. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain research. vol 1168. 2008-01-09. PMID:17706618. |
rb1cc1 insufficiency causes neuronal atrophy through mtor signaling alteration and involved in the pathology of alzheimer's diseases. |
2008-01-09 |
2023-08-12 |
Not clear |
| Tokuhiro Chano, Hidetoshi Okabe, Christine M Hulett. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain research. vol 1168. 2008-01-09. PMID:17706618. |
to clarify whether rb1cc1 insufficiency is involved in neuronal atrophy and alzheimer's pathology, we investigated modifications of rb1cc1 as a possible cause of atrophy or death through the disturbance of mtor signaling in neuro-2a neuroblastoma cells. |
2008-01-09 |
2023-08-12 |
Not clear |
| Tokuhiro Chano, Hidetoshi Okabe, Christine M Hulett. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain research. vol 1168. 2008-01-09. PMID:17706618. |
we also evaluated the correlation between rb1cc1 and mtor signaling in a series of alzheimer's brain tissues. |
2008-01-09 |
2023-08-12 |
Not clear |
| Tokuhiro Chano, Hidetoshi Okabe, Christine M Hulett. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain research. vol 1168. 2008-01-09. PMID:17706618. |
both tsc1 and rb1cc1 were equally functional and maintained mtor signaling, indicated by phospho-s6 (ser240/244) expression in 69% of alzheimer's (9/13 cases) and 100% of normal brains (6/6 cases). |
2008-01-09 |
2023-08-12 |
Not clear |
| Erik S Carlson, John D H Stead, Charles R Neal, Anna Petryk, Michael K Georgief. Perinatal iron deficiency results in altered developmental expression of genes mediating energy metabolism and neuronal morphogenesis in hippocampus. Hippocampus. vol 17. issue 8. 2007-10-31. PMID:17546681. |
id altered gene expression in the mammalian target of rapamycin (mtor) pathway and in a gene network implicated in alzheimer disease etiology. |
2007-10-31 |
2023-08-12 |
human |
| Marc Paccalin, Stéphanie Pain-Barc, Claudette Pluchon, Chloé Paul, Marie-Noelle Besson, Anne-Sophie Carret-Rebillat, Agnès Rioux-Bilan, Roger Gil, Jacques Hugo. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 22. issue 4. 2007-01-04. PMID:16954686. |
activated mtor and pkr kinases in lymphocytes correlate with memory and cognitive decline in alzheimer's disease. |
2007-01-04 |
2023-08-12 |
Not clear |
| Marc Paccalin, Stéphanie Pain-Barc, Claudette Pluchon, Chloé Paul, Marie-Noelle Besson, Anne-Sophie Carret-Rebillat, Agnès Rioux-Bilan, Roger Gil, Jacques Hugo. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 22. issue 4. 2007-01-04. PMID:16954686. |
the control of translation, involving the kinases mtor (mammalian target of rapamycin) and pkr (double-stranded rna-dependent protein kinase), modulates cell survival and death and is altered in the brains of patients with alzheimer's disease (ad). |
2007-01-04 |
2023-08-12 |
Not clear |
| Xu Li, Irina Alafuzoff, Hilkka Soininen, Bengt Winblad, Jin-Jing Pe. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. The FEBS journal. vol 272. issue 16. 2005-09-30. PMID:16098202. |
levels of mtor and its downstream targets 4e-bp1, eef2, and eef2 kinase in relationships with tau in alzheimer's disease brain. |
2005-09-30 |
2023-08-12 |
Not clear |